Founded in 1935 in Parma ( Italy), the Chiesi Group achieved a turnover of 1,056 million Euro in 2011, up by 4.1% on the previous year. The Group, currently has a total of 25 affiliates worldwide and is present in over 60 countries with its drugs, which are produced at plants in Parma, Blois (France) and Santana de Parnaiba ( Brazil). In 2011 investment in R&D reached 169.3 million Euro, equivalent to 16% of the turnover. The R&D centres in Parma, Paris, Rockville ( USA) and Chippenham (UK) integrate their efforts to work together on the Group's pre-clinical, clinical and registration programmes. At the end of 2011, the Chiesi Group's total staff stood at over 3,800 people, more than 320 of whom are dedicated to R&D.
The main areas of activity are in respiratory therapeutics and specialist medicine areas. A clear shift occurred in the last years towards more innovative molecules. The respiratory pipeline now comprises several classes of novel bronchodilating agents (Long acting muscarinic antagonists, bifunctional muscarinic antagonists-Βeta2 Agonits) and anti-inflammatory agents (PDE4 inhibitors, p38 kinase inhibitors, Neutrophil Elastase Inhibitors) that provide opportunities for future innovative fixed combinations for the treatment of asthma and COPD.
SOURCE Chiesi Farmaceutici S.p.A.